Beyond Medicine (CEO Daehyun Kim), a digital therapeutic device specialist, announced on the 24th that its temporomandibular joint disorder (TMD) treatment and management software, 'Clickless', has received approval as a Class 2 digital medical device from the Ministry of Food and Drug Safety.
TMJ disorder (TMJD) is primarily caused by behavioral and psychological factors, such as stress, teeth grinding, and poor oral habits. Existing treatments, which primarily focus on physical therapy and medication, have limitations, with relapse rates reaching approximately 50%. To address this, Clickless offers a six-week digital treatment program that combines cognitive behavioral therapy (CBT)-based behavioral modification, meditation-based relaxation therapy, masticatory muscle rehabilitation exercises, and data-driven treatment monitoring.
Patients can receive lifestyle modifications and behavioral factor analysis via their smartphones, while medical staff can review treatment data and develop personalized treatment plans through a dedicated dashboard. Clickless was the first dental device to be designated as an innovative medical device by the Ministry of Food and Drug Safety. In a clinical trial at Hallym University Hospital, it was confirmed to be effective in reducing pain by an average of three times in over 96% of patients. The results of this study were published in the Journal of Medical Internet Research (JMIR).
Beyond Medicine participated in the "2025 Unicorn Bridge with Samsung Fire & Marine Insurance" program, advancing the advancement and subsequent commercialization of its AI-based TMD digital therapeutic device. Building on this approval, Beyond Medicine plans to participate in CES 2026 Seoul Pavilion in January 2026 to explore global market expansion.
- See more related articles
You must be logged in to post a comment.